Health Affairs, 27, no. 1 (2008): 130-139 doi: 10.1377/hlthaff.27.1.130 © 2008 by Project HOPE	New Online Disparities in Health:   Obama aide on legislation   Smedley call to action   Shrink regulations first   A Real Policy Debate   Top 10 HA Articles Of '07

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Outterson, K. Articles by Kesselheim, A. S. PubMed PubMed Citation Articles by Outterson, K. Articles by Kesselheim, A. S. Related Collections Access To Care Consumer Issues International Issues Vaccines

Drugs & Vaccines

Market-Based Licensing For HPV Vaccines In Developing Countries

Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.

                      What's this?

This article has been cited by other articles:

				D. A Chokshi and A. S Kesselheim Rethinking global access to vaccines BMJ, April 5, 2008; 336(7647): 750 - 753. [Full Text] [PDF]

eLetters: